### Endometrial Carcinoma

**ENDO-B**

**Internal request:**
Add docetaxel as a systemic therapy option for the treatment of recurrent, metastatic or high-risk disease in endometrial carcinoma

Based upon discussion and the noted reference, the panel consensus was to add docetaxel (category 2B) as a systemic therapy option for the treatment of recurrent, metastatic or high-risk disease in endometrial carcinoma. A corresponding footnote was added that states, “Docetaxel may be considered for patients in whom paclitaxel is contraindicated.”

**References:**

**Vote:**
- YES: 12
- NO: 4
- ABSTAIN: 2

---

**Endometrial Carcinoma**

**ENDO-B**

**Internal request:**
Add bevacizumab as a systemic therapy option for the treatment of recurrent, metastatic or high-risk disease in endometrial carcinoma

Based upon discussion and the noted reference, the panel consensus was to add bevacizumab (category 2B) as a systemic therapy option for the treatment of recurrent, metastatic or high-risk disease in endometrial carcinoma. A corresponding footnote was added that states, “Bevacizumab may be considered for use in patients who have progressed on prior cytotoxic chemotherapy.”

**References:**

**Vote:**
- YES: 10
- NO: 6
- ABSTAIN: 2